Recent Publications on : |  |
Fold-recognition and comparative modeling of human beta3GalT I, II, IV, V and VI and beta3GalNAcT I: prediction of residues conferring acceptor substrate specificity.
beta3GalTs are type II transmembrane proteins that transfer galactose from...
Direct Link | 12th October, 2007
| School of Biosciences and Bioengineering, Indian Institute of Technology
|
Comprehensive enzymatic characterization of glycosyltransferases with a beta3GT or beta4GT motif.
Bioinformatics is a very powerful tool in the field of glycoproteomics, as...
Direct Link | 18th May, 2007
| Glycogene Function Team of Research Center for Glycoscience, National
|
Comparative analysis of retroviral and native promoters driving expression of beta1,3-galactosyltransferase beta3Gal-T5 in human and mouse tissues.
Beta1,3-galactosyltransferase beta3Gal-T5 is highly expressed in the...
Direct Link | 9th February, 2007
| Department of Biomedical Sciences Experimental and Clinical, University of
|
Glycosyltransferases involved in type 1 chain and Lewis antigen biosynthesis exhibit glycan and core chain specificity.
Sialyl Lewis A (SLe(a)), Lewis A (Le(a)), and Lewis B (Le(b)) have been...
Direct Link | 23rd August, 2006
| Division of Clinical Immunology, Karolinska Institutet, Karolinska
|
Endogenous retrovirus long terminal repeats as ready-to-use mobile promoters: the case of primate beta3GAL-T5.
Throughout the course of vertebrate evolution, germline retroviral...
Direct Link | 4th May, 2006
| Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia,
|
| A high proportion of chromosome 21 promoter polymorphisms influence transcriptional activity.
| 26th January, 2005
| Department of Psychological Medicine, University of Wales College of
|
Association between expression levels of CA 19-9 and N-acetylglucosamine-beta;1,3-galactosyltransferase 5 gene in human pancreatic cancer tissue.
OBJECTIVE: CA 19-9, equivalent to Sialyl Lewis antigen, is a well-known...
Direct Link | 4th June, 2004
| Department of Surgery and Clinical Oncology, Graduate School of Medicine,
|
| Suppression of beta 1,3galactosyltransferase beta 3Gal-T5 in cancer cells reduces sialyl-Lewis a and enhances poly N-acetyllactosamines and sialyl-Lewis x on O-glycans.
| 10th March, 2004
| Department of Biomedical Sciences Experimental and Clinical (DSBSC),
|
An endogenous retroviral long terminal repeat is the dominant promoter for human beta1,3-galactosyltransferase 5 in the colon.
LTRs of endogenous retroviruses are known to affect expression of several...
Direct Link | 6th January, 2004
| Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC,
|
